Please select the eligibility criteria that correspond to the clinical trial below.
Title: Understanding and Appraising the New Medicine Service in England
Brief Summary: About 25% medicines prescribed for long term conditions are not taken as directed, and approximately 15% people receiving a new medicine take few, if any, doses. The New Medicine Service (NMS) is a community pharmacy service that started in England in October 2011 which involves the pharmacist providing additional support to patients starting a new medicine for some breathing problems (asthma \& COPD), high blood pressure, adult onset diabetes or medicines which reduce blood clotting. It aims to improve the way patients take their medicines improving outcomes and reducing costs to the National Health Service (NHS).

The investigators will assess the effectiveness and cost effectiveness of the NMS using a research study where some people will receive the NMS, and some won't, so The investigators can look at the effect of the NMS on problems with their medicines, medicines taking and use of the NHS in general. Data will be collected in the East Midlands, South Yorkshire and London areas.

The investigators will recruit 500 patients from a range of different pharmacies and follow them up at six, ten and twenty six weeks after starting their new medicine to assess effects on medicines taking behaviour, patients' reported problems with medicines, referrals to their General Practitioner (GP) and use of NHS resources. The investigators will compare the data gathered from this study with that being collected routinely by all pharmacies in England to provide wider estimates of cost effectiveness.

The investigators will also explore how the NMS service is being implemented by pharmacies. A sample of patients from the main study will be followed in more detail. This will involve recording the consultations with the pharmacist and also interviewing patients about their experience of the service. The investigators will interview the patients GP to investigate their views of the service. The investigators will also try to understand why people decline the invitation for the NMS


Options:
A: Inclusion Criteria:

* Males or females, age 21-85
* Taking 0-3 antihypertensive medications with no changes in regimen or dose within the past 4 weeks
* Non-diabetic with clinic BP 145-179 / 95-109 or diabetic with BP greater than 135/85

Exclusion Criteria:

* Previous 24 hour BP monitoring consult service within the past 6 months
* Stage 3 hypertension greater than 180/110
* Recent MI or stroke within the past 6 months
* Class III or IV congestive heart failure
* Unstable angina
* Uncontrolled atrial fibrillation
* Serious renal disease (serum creatinine greater than 3.5)
* Serious hepatic disease (total bilirubin greater than 3.0)
* Pregnancy
* Poor prognosis with less than a 3 year life expectancy
B: Inclusion Criteria:

* Diagnosis of hypertension in the prior two years and on hypertension medications
* Access to the Internet and an e-mail address
* Ability to use a computer using the English language
* Medical care coverage which permits them to refill prescriptions at Group Health Cooperative pharmacies and a willingness to do so.
* Blood pressure on each of two screening visits averaging \> 90 mmHg diastolic or \> 140 mmHg systolic and \< 110 mmHg diastolic or \< 200 mmHg systolic

Exclusion Criteria:

* Diagnosed or history of diabetes, cardiovascular disease (ischemic heart disease, valvular heart disease, heart failure, arrhythmias, strokes or transient ischemic attacks, and peripheral vascular disease)
* Current treatment for cancer, on immunosuppressant or antiretroviral treatment.
* Surgery or hospitalization in the prior 3 months
* Pregnancy (or plans to become pregnant in the next 12 months)
* Plans to move out of the area or leave the health plan in the next 12 months.
* Upper arm circumference size \> 18 inches.
* Arrhythmia detected at screening visits
C: Inclusion Criteria:

* Subject with asthma diagnosed according to criteria of the Global Strategy for Asthma Management and Prevention;
* Subject is a male or female with 18 to 73 years-old;
* Subject who has access to medications supplied by the the Brazil Heath Care System;
* Subject unable to perform the procedures or conditions such as pregnancy that may affect the results of the study;
* Literate subject without Cognitive Disorders, Alzheimer's, Dementia, that can limit the ability to participate in this study;
* Subject who have availability to attend the monthly meetings;
* Subject provides written informed consent and attend the first evaluation.

Exclusion Criteria:

* Subject who cannot be classified in the inclusion criteria.
D: Inclusion Criteria:

* Community dwelling patients eligible for NMS (aged from 14 years starting a new medicine for asthma/COPD, diabetes (Type 2), antiplatelet/anticoagulation or hypertension).

Exclusion Criteria:

* Patients collecting a repeat prescription for a medicine (i.e. not new) for asthma/COPD, type 2 diabetes mellitus (T2DM), antiplatelets/anticoagulants or hypertension
* Patients collecting a medicine where the only change from the previous medicine involves a dosage or formulation change only
* Participants who are unable to understand patient/participant study documents
* Participants who are unable and unwilling to provide written consent / assent

Answer: D